• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

byJessie WillisandTeddy Guo
August 3, 2022
in Chronic Disease, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to placebo, methotrexate did not significantly reduce the risk of the development of clinical arthritis in at-risk patients.

2. Methotrexate significantly improved patient-reported symptoms, MRI-detected join inflammation, and physical impairments compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rheumatoid arthritis (RA) is an autoimmune disease which can cause significant pain, stiffness, and swelling of the joints. While methotrexate is commonly used in the treatment of RA, its use has not been studied in the pre-arthritis phase. The TREAT EARLIER study enrolled patients with arthralgia who were clinically suspected to be at-risk of rheumatoid arthritis by a rheumatologist and had MRI findings of joint inflammation. Patients were randomized to receive either methotrexate or placebo. The study found no significant benefit in the prevention of clinical arthritis in the treatment group compared to the control. However, the treatment group had significantly lower patient-reported symptoms of functional disease burden including pain, morning stiffness and presenteeism. Additionally, MRI-detected joint inflammation was shown to be lower in the treatment group compared to placebo. Serious adverse events were similar between both groups and side effects from methotrexate were consistent with its known safety profile. Despite not being effective at preventing clinical arthritis, methotrexate was shown to have benefit in reducing the burden of disease in patients at-risk of rheumatoid arthritis.

Click to read the study in The Lancet

Relevant Reading: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

RELATED REPORTS

Inebilizumab improves outcome in patients generalized myasthenia gravis

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis

In-Depth [randomized controlled trial]: The TREAT EARLIER trial was run at a single centre in the Netherlands. The study enrolled participants with arthralgia aged 18 years or older at risk of developing rheumatoid arthritis as clinically suspected by a rheumatologist. Subclinical joint inflammation was confirmed by MRI. A total of 236 patients were enrolled and randomly assigned 1:1 to either treatment group (n=119) or placebo group (n=117). Treatment was a single intramuscular glucocorticoid injection of 120 mg methylprednisolone followed by a 52-week course of methotrexate. Dosage was titrated upward to 25 mg methotrexate weekly or the highest tolerated dose. They were followed for one year following treatment and self-reported symptoms every 4 months. The primary outcome was the development of clinical arthritis as defined by the 2010 rheumatoid arthritis classification criteria or involving two or more joints for at least 2 weeks.

During the two-year treatment and follow-up period, the occurrence of clinical arthritis was 19% of the treatment group versus 18% of the placebo group (HR 0.81 [95% CI 0.45 to 1.48]). However, patient-reported symptoms of decreased physical functioning (p=0.0042), pain (p<0.0001), morning stiffness (p<0.0001), and presenteeism (p=0.0007) were significantly lower in the treatment group compared to placebo. MRI-detected joint inflammation was also significantly lower in the treatment group compared to placebo (-1.4 points, -2.0 to -0.9, p<0.0001). Serious adverse events were equal in both groups and adverse events were consistent with the known safety profile of methotrexate.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arthralgiaarthritisjoint inflammationjoint painmethotrexaterheumatoid arthritisrheumatology
Previous Post

Magnetic resonance cholangiopancreatography diagnoses bile duct obstruction with high sensitivity and specificity [Classics Series]

Next Post

Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-Year clinical outcomes

RelatedReports

Age and number of islet autoantibodies associated with diabetes risk
Neurology

Inebilizumab improves outcome in patients generalized myasthenia gravis

July 10, 2025
Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

June 9, 2025
#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis
StudyGraphics

#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis

May 30, 2025
Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

May 21, 2025
Next Post
Rivaroxaban after TAVR linked with increased risk of adverse events compared to antiplatelet therapy

Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-Year clinical outcomes

Characteristic differences between young children and adolescents who die by suicide

Increased maternal milk feeding associated with improved neurodevelopmental outcomes for former preterm infants

#VisualAbstract: Nonoperative management of uncomplicated acute appendicitis comparable to appendectomy but leads to increased length of stay and disease recurrence

#VisualAbstract: Nonoperative management of uncomplicated acute appendicitis comparable to appendectomy but leads to increased length of stay and disease recurrence

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
  • Structured exercise intervention improves survival in colon cancer patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.